Ginkgo Bioworks Q3 revenue falls compared to last year
DNA•Ginkgo Bioworks’ third-quarter revenue fell 6% year over year to $28 million, while its net loss narrowed to $41 million from $73 million. The company reaffirmed its 2026 total cash burn guidance of $125 million to $150 million.
1. Quarterly results
Ginkgo Bioworks reported third-quarter revenue of $28 million, down 6% from a year earlier. Net loss narrowed to $40.98 million from $73 million, and loss per share was $0.64.
2. Contracts and outlook
The company cited an autonomous lab sale to Novo and new government contracts as drivers. It said Cloud Lab attracted new pharmaceutical and AI customers for data generation services, and it signed 22 ADME customers, including 20 first-time customers. Ginkgo reaffirmed 2026 total cash burn guidance of $125 million to $150 million and expects growth in autonomous lab sales with new pharmaceutical and government contracts.
